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LETTER TO THE EDITOR
Sialyl Tn as a prognostic marker in epithelial ovarian cancer
Sir - Monoclonal antibodies (MoABs) that recognise the
carbohydrate structures of cell-surface glycoproteins and
glycolipids of cancer cells have been regarded as useful tools
for characterising cell types and for cancer diagnosis through
assaying of antigenic glycoconjugates secreted into the
bloodstream (Bast et al., 1983; Fukushi et al., 1985; Nozawa
et al., 1989). Serum CA125 levels reflect tumour burden and
the change in CA125 level accurately reflects disease status
(Zanaboni et al., 1987). By monitoring CA125 levels during
treatment, it has been possible to predict response to therapy
and to prognosticate survival (Niloff et al., 1986). New
moABs (TKH-1 and TKH-2) recognising a core structure of
mucin-type carbohydrate chain have been made (Kjeldsen et
al., 1988). These moABs directed to the tumour associated
0-linked sialyl 2-6-a-Acetylgalactosaminyl (sialyl Tn; STN)
epitope were generated by immunisation with ovine submax-
illary mucin. Cell surface glycoconjugates, the composition
has been shown to change during tumorigenesis, participate
in a variety of specific biological function. Prognostically
important differences in tumour biology may still be due to
qualitative changes in tumour mucin (Itzkowitz et al., 1990).
Qualitative rather than quantative mucin alterations might be
important in the biology of cancer. To confirm this pos-
sibility, we investigated to determine whether circulating
serum levels of STN antigen, which may play a role in the
biological behaviour, might influence the prognosis of
patients with ovarian cancer.
Serum samples were obtained from 89 patients with histo-
logically proven epithelial ovarian cancer. Staging of ovarian
cancer according to the FIGO classification showed 23
patients with stage I, 18 with stage II, 38 with stage III, and
10 with stage IV. All patients were initially treated with
optimal debulking surgery followed by five cycles of com-
bination chemotherapy including cisplatin 50 mg m-2, adria-
mycin 50 mgm-2, and cyclophosphamide 500 mgm-2. Se-
rum samples were obtained within 2 weeks before therapy
and stored at - 80°C until use. Circulating serum STN
antigen concentrations (Uml') were determined by a com-
petitive immunoradiometric assay kit, supplied by Otsuka
Assay Laboratories (Tokushima, Japan) that use moAB
TKH-2 in a one step procedure (Kobayashi et al., 1991).
The results demonstrate that per cent survival at 5 years
for patients with STN-positive (serum STN levels ) 50 U-
ml-'; n = 37) versus STN-negative (<50 U ml-'; n = 52)
tumours was 11% versus 77%, respectively (P<0.05 [Figure
1]). The STN-positive patients had a shorter 5-year
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Figure 1 Probability of survival in patients with ovarian cancer
according to STN status. Five-year survival rate for patients with
STN-positive (-; serum STN levels > 50 u ml-') versus STN-
negative (---; <50 Uml-') tumours was 11% vs 77%, respec-
tively (P<0.05).
progression-free interval (PFI) than those with STN-negative
cases (5% vs 52%; P<0.05). The poor survival rate of
STN-positive patients might reflect their higher tumour
burden. STN has been shown to be associated with early
relapse of this malignancy.
Multivariate regression analysis was performed to further
evaluate potential prognostic factors, indicating that stages
(III and IV), STN positivity (serum STN levels > 50 U ml-'),
Performance Status (PS 3 and 4), and histologic grade (grade
3) were significant negative predictors of survival in this
order. No significant correlation was found between these
factors and serum STN levels. STN has been shown to be
independently associated with prognosis and a strong predic-
tor of survival. This antigen could be of considerable impor-
tance for deciding which postresection patients might need
further additional therapy.
H. Kobayashi, T. Terao & Y. Kawashima
The Department of Obstetrics and Gynecology,
Hamamatsu University School of Medicine,
Hando-cho 3600, Hamamatsu, Shizuoka, 431-31, Japan.
References
BAST, R.C., KLUG, T.L., ST. JOHN, E., JENISON, E., NILOFF, J.M.,
LAZARUS, H., BERKOWITZ, R.S., LEAVITT, T., GRIFFITHS, C.T.,
PARKER, L., ZURAWSKI, V.R. & KNAPP, R.C. (1983). A radio-
immunoassy using a monoclonal antibody to monitor the course
of epithelial ovarian cancer. New Engi. J. Med., 309, 883.
FUKUSHI, Y., KANNAGI, R. & HAKOMORI, S. (1985). Location and
distribution of difucoganglioside (VI3NeuAc3V3III Fuc2 nLc6) in
normal and tumor tissues defined by its monoclonal antibody
FH-6. Cancer Res., 45, 3711.
ITZKOWITZ, S.H., BLOOM, E.J., KODAL, W.A., MODIN, G., HAKO-
MORI, S. & KIM, Y.S. (1990). Sialosyl Tn: A novel mucin antigen
associated with prognosis in colorectal cancer patients. Cancer,
66, 1960.
KJELDSEN, T., CLAUSEN, H., HIROHASHI, S., OGAWA, T., IIJIMA, H.
& HAKOMORI, S. (1988). Preparation and characterization of
monoclonal antibodies directed to the tumor-associated 0-linked
sialosyl-2-6a-N-acetylgalactosaminyl (sialosyl-Tn). Cancer Res.,
48, 2211.
KOBAYASHI, H., TERAO, T. & KAWASHIMA, Y. (1991). Clinical
evaluation of circulating serum sialyl Tn antigen levels in patients
with epithelial ovarian cancer. J. Clin. Oncol., 9, 983.
NILLOF, J.M., KNAPP, R.C. & LAVIN, P.T. (1986). The CA125 assay
as a predictor of clinical recurrence in epithelial ovarian cancer.
Am. J. Obstet. Gynecol., 155, 56.LETTER TO THE EDITOR 985
NOZAWA, S., YAJIMA, M., KOJIMA, K., IIZUKA, R., MOCHIZUKI, H.,
SUGAWARA, T., IWAMORI, M. & NAGAI, Y. (1989). Tumor-
associated mucin-type glycoprotein (CA54/61) defined by two
monoclonal antibodies (MA54 and MA61) in ovarian cancers.
Cancer Res., 49, 493.
ZANABONI, F., VERGADORO, F., PRESTI, M., GALLOTTI, P., LOM-
BARDI, F. & BOLIS, G. (1987). Tumor antigen CA125 as a marker
of ovarian epithelial carcinoma. Gynecol. Oncol., 28, 61.